| Literature DB >> 28224564 |
Konstantinos Vardas1,2, Stavroula Ilia2, Amalia Sertedaki3, Evangelia Charmandari3, Efrossini Briassouli4, Dimitris Goukos4, Kleovoulos Apostolou1, Katerina Psarra5, Efthimia Botoula6, Stylianos Tsagarakis6, Eleni Magira1, Christina Routsi1, Constantine A Stratakis7, Serafim Nanas1, George Briassoulis8.
Abstract
BACKGROUND: The purposes of this study are to examine if the human glucocorticoid receptor (hGR) isoform-α mRNA and hGR protein expressions are deficient in the acute phase of sepsis (S) compared to systemic inflammatory response syndrome (SIRS) and healthy subjects (H) and to evaluate if the hGRα and hGR alterations are associated with cortisol changes and if they are related to (1) extracellular and intracellular heat shock proteins (HSP) 72 and 90α; (2) ACTH, prolactin, and interleukins (ILs); and (3) outcome.Entities:
Keywords: Cortisol; Glucocorticoid receptor (GR); HSP90α; Heat shock protein 72; SIRS; Sepsis
Year: 2017 PMID: 28224564 PMCID: PMC5319939 DOI: 10.1186/s40635-017-0123-8
Source DB: PubMed Journal: Intensive Care Med Exp ISSN: 2197-425X
Fig. 1Glucocorticoids (GC) diffuse across the cell membrane and bind to human glucocorticoid receptor (hGR) in the cytoplasm. In a heat shock protein (HSP) heterocomplex, hGRα is activated (upon ligand binding), is released from HSP72 and HSP90α, and rapidly translocates into the nucleus, where the transcription of target genes is initiated. Through transactivation, binding of two hGRα molecules together as a homodimer to glucocorticosteroid response elements (GRE) in the promoter region of steroid-sensitive genes leads to the transcription of genes encoding anti-inflammatory mediators (i.e., IL-10) and the inhibition of nuclear factor-κB (NF-κB). Through transrepression, the hGRα–GC complex interacts with the activated by NF-κB and other pro-inflammatory transcription factors with intrinsic histone acetyltransferase (HAT) activity switching off multiple activated inflammatory genes (i.e., IL-6). CBP cAMP response element binding protein, IKKβ inhibitor of I-κB kinase-β
Baseline characteristics at study enrollment and group differences
| Healthy subjects ( | SIRS ( | Sepsis ( | Statistic value | Effect size ( |
| |
|---|---|---|---|---|---|---|
| Age (years)e | 35 (28–50)a | 41 (32–53)c | 58 (44–69)a, c | 34 | 0.29 | <0.001 |
| Gender (male/female) | 19/16 | 31/9 | 28/20 | 5.2 | 0.21 | 0.07 |
| Mortality in ICU (died/survived (%)) | 0/35 | 5/35 (12.5%) | 21/27 (43.8%) | 10.2 | 0.34 | 0.001 |
| Mortality in hospital (died/survived (%)) | 0/35 | 6/34 (15.8%) | 29/19 (60.4%) | 17.5 | 0.45 | <0.001 |
| LOS (days) | NA | 15.5 (7–28.5) | 18.5 (9.2–36.8) | 2 | 0.03 | 0.16 |
| APACHE II | NA | 15 (10–18)c | 21 (16–27)c | 15 | 0.19 | <0.001 |
| SOFA | NA | 9 (7–11)c | 11 (9–13)c | 11 | 0.14 | 0.001 |
| SAPS III | NA | 41 (43–58)c | 41 (61–78)c | 32 | 0.44 | <0.001 |
| CRP (mg/dl) | NA | 7.1 (1.05–15)c | 21 (8.8–27)c | 10.5 | 0.15 | 0.001 |
| PCT (ng/ml) | NA | 0.9 (0.5–1.8)c | 5.2 (1–34)c | 7 | 0.23 | 0.008 |
| Lactate | NA | 2.4 (1.4–4.2) | 2.8 (1.3–5) | 0.23 | 0.00 | 0.63 |
| Glucose (mg/dl) | NA | 154 (128–189)c | 219 (145–299)c | 8.6 | 0.12 | 0.003 |
| Albumin (g/dl) | NA | 3 (2.3–3.4)c | 2.5 (2.1–2.9)c | 6.3 | 0.09 | 0.012 |
| WBC (K/μl) | NA | 11.4 (7.3–15.5) | 10.9 (2.6–19.9) | 0.12 | 0.00 | 0.91 |
| hGRα mRNA (fold change) | 0.50 (0.12–0.9)a | 0.64 (0.32–0.77) | 0.74 (0.52–1.23)a | 8.3 | 0.08 | 0.016 |
| hGR (MFI) | 0.95 (0.76–1.9)a | 1.1 (0.43–2.5)c | 3.3 (1.6–4.6)a, c | 9.6 | 0.28 | 0.008 |
| Prolactin (ng/ml) | 7.5 (5–10)a b | 18.3 (11–25)b | 15.4 (9–32)a | 20.4 | 0.17 | <0.001 |
| Cortisol (μg/dl) | 12.3 (9–15)a | 16.2 (11–23)c | 32.8 (21–67)a, c | 38.6 | 0.33 | <0.001 |
| ACTH (pg/ml) | 17.5 (13–33)b | 10 (6–19)b, c | 18.6 (10–38)c | 10.4 | 0.09 | –0.005 |
| eHSP90α (ng/ml) | 10.5 (1.2–23)a, b, c | 32 (22–57)b, c | 71 (31–124)a, c | 39.5 | 0.33 | <0.001 |
| eHSP72 (ng/ml) | 0.26 (0.14–0.41)a | 0.29 (0.19–0.49)c | 0.95 (0.41–2.5)a, c | 32 | 0.29 | <0.001 |
| mHSP90α (MFI) | 24 (12–82) | 36 (10.5–64) | 33 (7.6–56) | 0.07 | 0.00 | 0.96 |
| mHSP72 (MFI) | 19.6 (13–32) | 22.8 (11–52) | 18 (11.7–30.7) | 0.84 | 0.01 | 0.65 |
| nHSP90α (MFI) | 11 (5.4–25) | 17 (4.8–25) | 18.3 (6.8–38) | 3.5 | 0.03 | 0.17 |
| nHSP72 (MFI) | 77 (44–110)a | 75 (28–154)c | 40 (25–65)a, c | 13.7 | 0.12 | 0.001 |
| IL-6 (pg/ml) | 1.4 (0.98–2.5)a, b | 77 (21–213)b | 203 (60–539)a | 72 | 0.60 | <0.001 |
| IL-10 (ng/ml) | 0.01 (0.1–9.5) a | 4.9 (0.1–11)c | 48 (0.1–58)a, c | 15.6 | 0.13 | <0.001 |
| IL-17 (ng/ml) | 0.2 (0.2–33) | 0.2 (0.2–6.4) | 0.2 (0.2–7.8) | 0.05 | 0.00 | 0.98 |
| IFN-γ (pg/ml) | 6.2 (0.44–9.8) | 4.7 (0.13–7.8)c | 9.7 (4–17)c | 12 | 0.10 | 0.03 |
APACHE Acute Physiology and Chronic Evaluation, CRP C-reactive protein, hGRα human glucocorticoid receptor α-isoform, eHSP extracellular heat shock protein, nHSP neutrophil-HSP, mHSP monocyte-HSP, IFN-γ interferon gamma, IL interleukin, MFI mean fluorescence intensity, PCT procalcitonin, SAPS III Simplified Acute Physiology Score, SIRS systematic inflammatory response syndrome, SOFA Sequential Organ Failure Assessment, WBC white blood cells
**Per Cohen for df = 2, the effect size should be viewed as small 0.07, medium 0.21, and large 0.35
***Asymptomatic significance (two-sided test) using the independent samples Kruskal–Wallis test; a p value <0.05 was considered statistically significant
a–cDunn-Bonferroni multiple comparisons (all pairwise): a p < 0.05 between healthy subjects and S groups, b p < 0.05 between healthy subjects and SIRS groups, c p < 0.05 between S and SIRS groups
dSeptic shock, n = 25 (60%)
eData are expressed as median (IQR, interquartile range)
Fig. 2Bivariate correlations of monocyte hGR protein (MFI) with a hGRα mRNA (r s = 0.64, p < 0.001); b cortisol (r s = 0.38, p < 0.03); c eHSP72 (r s = 0.41, p < 0.02); d eHSP90α (r s = 0.33, p < 0.05); e IL-6 (r s = 0.50, p < 0.003); f IL-10 (r s = 0.40, p < 0.025); g mHSP90α (r s = 0.60, p < 0.001); h SOFA score (r s = 0.56, p < 0.03); j PO2/FiO2 (r s = −0.76, p < 0.005) (Spearman’s rank correlation tests). hGRα human glucocorticoid receptor isoform-α, HSP heat shock protein, IL interleukin, e extracellular m monocyte, SOFA Sequential Organ Failure Assessment
Fig. 3Comparisons between survivors and non-survivors in the sepsis and SIRS subcohorts, regarding a severity of illness, b hormonal, c glucocorticoid receptor, d extracellular and e intracellular innate immune, and f inflammatory acute stress response. The p value was calculated using the Mann-Whitney U test and a p value <0.05 (two sided) was considered statistically significant. Sepsis and/or mortality was associated with or had a trend for increased severity of illness, expression of extracellular HSP90α and HSP72, cytokines, cortisol, and GR and a trend for lower intracellular HSP72. Asterisk indicates p < 0.05 between non-survivors and survivors in each diagnostic group; number sign indicates p < 0.05 between sepsis and SIRS in each outcome group. SIRS systemic inflammatory response syndrome, APACHE II Acute Physiology and Chronic Evaluation, SOFA Sequential Organ Failure Assessment, SAPS III Simplified Acute Physiology Score III, GR glucocorticoid receptor, HSP heat shock protein, IL interleukin, IFN-γ interferon gamma, MFI mean fluorescence intensity
Fig. 4Area under the receiver operating characteristic curve (AUROC) for a discriminating sepsis in ICU patients: eHSP72, cortisol, and hGR MFI best discriminated sepsis from SIRS as indicated by an AUROC > 0.85; b AUROC for predicting mortality among patients with sepsis (Sepsis-3 definition): eHSP72 and hGR MFI were strong predictors of mortality, achieving an AUROC > 0.95. hGRα human glucocorticoid receptor isoform-α, HSP heat shock protein, MFI mean fluorescence intensity
Receiver operating characteristic curve analysis to determine the optimum cutoff values and the positive and negative predictive values of hGR, cortisol, and HSPs for the prediction of sepsis in ICU patients
| Parameters | ||||||||
|---|---|---|---|---|---|---|---|---|
| Biomarkers | AUROC (95% CI) |
| Sensitivity | Specificity |
| Cutoff | PPV (%) | NPV (%) |
| eHSP72 | 0.94 (0.84–1.0) | 0.001 | 0.88 | 0.79 | 0.66 | 0.40 | 73 | 68 |
| Cortisol | 0.90 (0.77–1.0) | 0.002 | 1.00 | 0.79 | 0.79 | 15.7 | 66 | 70 |
| hGR MFI | 0.85 (0.69–1.0) | 0.008 | 0.88 | 0.79 | 0.66 | 2.66 | 73 | 49 |
| eHSP90α | 0.80 (0.62–0.99) | 0.02 | 0.75 | 0.79 | 0.54 | 66.0 | 72 | 56 |
| hGRα mRNA | 0.75 (0.52–0.98) | 0.05 | 0.75 | 0.86 | 0.61 | 0.38 | 66 | 67 |
Abbreviations: AUROC area under the receiver operating characteristic curve, CI confidence interval, J Youden’s index, PPV positive predictive value, NPV negative predictive value, eHSP extracellular heat shock protein, hGR human glucocorticoid receptor, MFI mean fluorescent intensity
Receiver operating characteristic curve analysis to determine the optimum cutoff values and the positive and negative predictive values of hGR, cortisol, and HSPs for the prediction of mortality in ICU patients with Sepsis-3
| Parameters | ||||||||
|---|---|---|---|---|---|---|---|---|
| Biomarkers | AUROC (95% CI) |
| Sensitivity | Specificity |
| Cutoff | PPV (%) | NPV (%) |
| hGR MFI | 1.00 (1.00–1.0)0 | 0.034 | 1.00 | 0.89 | 0.89 | 4.64 | 66 | 58 |
| eHSP72 | 1.00 (1.00–1.00) | 0.034 | 1.00 | 0.89 | 0.89 | 2.1 | 53 | 61 |
| eHSP90α | 0.79 (0.49–1.00) | 0. 23 | 1.00 | 0.67 | 0.67 | 137.6 | 44 | 56 |
Abbreviations: AUROC area under the receiver operating characteristic curve, CI confidence interval, J Youden’s index, PPV positive predictive value, NPV negative predictive value, eHSP extracellular heat shock protein, hGR human glucocorticoid receptor, MFI mean fluorescent intensity